Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO )
The ATS AP360 heart valve maximizes hemodynamic performance with a newsupra-annular cuff design that facilitates implantation. The original ATSMedical Open Pivot(R) Heart Valve is highly regarded for fundamental designfeatures that promote best-in-class hemodynamic performance, enhancedresistance to blood clot formation and improved patient quality of lifethrough quieter valve operation. In a response to the highly individualizedand specific valve selection criteria of cardiac surgeons, particularly withrespect to implantability, the ATS AP360 combines proven performance with acuff design that extends its appeal to a broader spectrum of surgeons.
Advertisement
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused oncardiac surgery. The Company, global in scope, is headquartered inMinneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves,which utilize a unique pivot design resulting in exceptional performance andlow risk profile, have been implanted in patients worldwide. The ATS 3f(R)brand encompasses multiple tissue heart valve product offerings at varyingsteps from market introductions to clinical trials to development projectsthat incorporate less invasive valve replacement technology. ATS Medical'sfocus on serving the cardiac surgery community is further strengthened byofferings that include ATS Simulus(R) annuloplasty products for heart valverepair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical website is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may includestatements regarding intent, belief or current expectations of the Company andits management. Actual results could differ materially from those projected inthe forward-looking statements as a result of a number of important factors,including the results of clinical trials, the timing of regulatory approvals,the integration of 3f Therapeutics and the surgical cryoablation business ofCryoCath Technologies, Inc., regulatory actions, competition, pricingpressures, supplier actions and management of growth. For a discussion ofthese and other risks and uncertainties that could affect the Company'sactivities and results, please refer to the Company's filings with theSecurities and Exchange Commission, including its Form 10-K for the year endedDecember 31, 2007 and its most recent quarterly report on Form 10-Q.
SOURCE ATS Medical, Inc.
